As EGFR and its downstream signaling pathways are closely related to autophagy regulation in various cancers, and targeting EGFR‐mediated autophagy is a potential strategy for cancer treatment,2 we explored whether osimertinib could induce autophagy by inhibiting EGFR and its downstream signaling pathways in BC. Here, EGFR is linked to breast cancer.